Should I buy or sell Cocrystal Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" COCP shares. View COCP analyst ratings or view top-rated stocks .

What is Cocrystal Pharma's stock price target for 2024?

1 Wall Street research analysts have issued 12 month target prices for Cocrystal Pharma's shares. Their COCP share price targets range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next year. This suggests a possible upside of 548.6% from the stock's current price. View analysts price targets for COCP or view top-rated stocks among Wall Street analysts .

How have COCP shares performed in 2023?

Cocrystal Pharma's stock was trading at $1.95 at the beginning of the year. Since then, COCP stock has decreased by 5.1% and is now trading at $1.85. View the best growth stocks for 2023 here .

Are investors shorting Cocrystal Pharma?

Cocrystal Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 9,800 shares, an increase of 84.9% from the October 31st total of 5,300 shares. Based on an average daily volume of 27,100 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.1% of the shares of the company are short sold. View Cocrystal Pharma's Short Interest .

When is Cocrystal Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our COCP earnings forecast .

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.48) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.48).

When did Cocrystal Pharma's stock split?

Shares of Cocrystal Pharma reverse split on Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA) , Hello Group (MOMO) , Intra-Cellular Therapies (ITCI) , Impala Platinum (IMPUY) , GenMark Diagnostics (GNMK) , Gevo (GEVO) , Auxly Cannabis Group (CBWTF) , Bionano Genomics (BNGO) , Blink Charging (BLNK) and Bilibili (BILI) .

How do I buy shares of Cocrystal Pharma?

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Cocrystal Pharma Stock Price, News & Analysis (NASDAQ:COCP)

$1.85

+0.01 (+0.54%)

(As of 11/29/2023 ET)

Compare

Today's Range: $1.70
▼
$1.90
50-Day Range: $1.46
▼
$2.13
52-Week Range: $1.38
▼
$3.29

Volume: 14,460 shs
Average Volume: 46,062 shs
Market Capitalization: $18.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

Cocrystal Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 548.6% Upside
$12.00 Price Target
Short Interest: Healthy
0.14% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.76
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.00) to ($1.87) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

406th out of 949 stocks

Pharmaceutical Preparations Industry

180th out of 435 stocks

3.5

Analyst's Opinion

Consensus Rating
Cocrystal Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, Cocrystal Pharma has a forecasted upside of 548.6% from its current price of $1.85.
Amount of Analyst Coverage
Cocrystal Pharma has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.14% of the float of Cocrystal Pharma has been sold short.
Short Interest Ratio / Days to Cover
Cocrystal Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cocrystal Pharma has recently increased by 84.91%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cocrystal Pharma does not currently pay a dividend.
Dividend Growth
Cocrystal Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for COCP.

2.1

News and Social Media Coverage

News Sentiment
Cocrystal Pharma has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Cocrystal Pharma this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cocrystal Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
25.06% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.43% of the stock of Cocrystal Pharma is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Cocrystal Pharma are expected to grow in the coming year, from ($2.00) to ($1.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cocrystal Pharma is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cocrystal Pharma is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cocrystal Pharma has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cocrystal Pharma Stock (NASDAQ:COCP)

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

COCP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

COCP Stock News Headlines

November 29, 2023 | finance.yahoo.com

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

November 27, 2023 | finance.yahoo.com

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 14, 2023 | benzinga.com

Cocrystal Pharma Stock (NASDAQ:COCP) Earnings Dates and Earning Calls

November 14, 2023 | msn.com

COCP: Cocrystal Pharma reports 3rd quarter financial results and provides updates on clinical trials.

November 13, 2023 | benzinga.com

Recap: Cocrystal Pharma Q3 Earnings

November 13, 2023 | finance.yahoo.com

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

November 9, 2023 | finance.yahoo.com

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 3, 2023 | markets.businessinsider.com

Buy Rating Issued for Cocrystal Pharma Amid Advancements in Influenza and Coronavirus Treatments

October 31, 2023 | finance.yahoo.com

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

October 5, 2023 | msn.com

HC Wainwright & Co. Reiterates Cocrystal Pharma (COCP) Buy Recommendation

October 2, 2023 | finance.yahoo.com

COCP: Cocrystal Pharma doses 1st subjects in the important CDI-988 clinical trial.

August 16, 2023 | finance.yahoo.com

COCP: Cocrystal Pharma reports 2nd quarter 2023 financial results and provides updates on drug pipeline.

August 15, 2023 | markets.businessinsider.com

Analyst Ratings for Cocrystal Pharma

August 15, 2023 | markets.businessinsider.com

Cocrystal Pharma (COCP) Receives a Buy from H.C. Wainwright

August 15, 2023 | markets.businessinsider.com

Noble Financial Keeps Their Buy Rating on Cocrystal Pharma (COCP)

August 14, 2023 | finance.yahoo.com

Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

August 11, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Immunocore Holdings (IMCR), Tyra Bioscience (TYRA)

August 8, 2023 | finance.yahoo.com

Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead

May 31, 2023 | finance.yahoo.com

Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988

May 24, 2023 | msn.com

HC Wainwright & Co. Maintains Cocrystal Pharma (COCP) Buy Recommendation

May 24, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Cocrystal Pharma (COCP)

May 17, 2023 | finance.yahoo.com

COCP: Cocrystal Pharma reports 1st quarter 2023 financial results and provides updates on drug pipeline.

May 15, 2023 | finance.yahoo.com

Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

May 4, 2023 | finance.yahoo.com

Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference

April 24, 2023 | finance.yahoo.com

Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors

See More Headlines

Receive COCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/03/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:COCP
CUSIP: N/A
CIK: 1412486
Web: www.cocrystalpharma.com
Phone: (305) 425-1780
Fax: N/A
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.00
High Stock Price Target: $12.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +566.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,840,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -54.10%
Return on Assets: -51.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.74
Quick Ratio: 16.74

Sales & Book Value

Annual Sales: $2.01 million
Price / Sales: 9.11
Cash Flow: $0.17 per share
Price / Cash Flow: 10.40
Book Value: $3.02 per share
Price / Book: 0.60

Miscellaneous

Outstanding Shares: 10,170,000
Free Float: 7,624,000
Market Cap: $18.31 million
Optionable: Not Optionable
Beta: 1.24

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Roger D. Kornberg Ph.D. (Age 76)
Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board
Comp: $125k
Dr. Sam Lee Ph.D. (Age 63)
Co-Founder, Co-CEO & President
Comp: $521.38k
Mr. James J. Martin CPA (Age 56)
M.B.A., Co-CEO, CFO & Corporate Secretary
Comp: $521.38k

Key Competitors

View All Competitors

Insiders

Phillip Md Et Al Frost
Bought 1,015,229 shares on 4/4/2023
Total: $2.00 M ($1.97/share)

View All Insider Transactions

COCP Stock Analysis - Frequently Asked Questions

Should I buy or sell Cocrystal Pharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" COCP shares.
View COCP analyst ratings or view top-rated stocks.
What is Cocrystal Pharma's stock price target for 2024?: 1 Wall Street research analysts have issued 12 month target prices for Cocrystal Pharma's shares. Their COCP share price targets range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next year. This suggests a possible upside of 548.6% from the stock's current price.
View analysts price targets for COCP or view top-rated stocks among Wall Street analysts.
How have COCP shares performed in 2023?: Cocrystal Pharma's stock was trading at $1.95 at the beginning of the year. Since then, COCP stock has decreased by 5.1% and is now trading at $1.85.
View the best growth stocks for 2023 here.
Are investors shorting Cocrystal Pharma?: Cocrystal Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 9,800 shares, an increase of 84.9% from the October 31st total of 5,300 shares. Based on an average daily volume of 27,100 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.1% of the shares of the company are short sold.
View Cocrystal Pharma's Short Interest.
When is Cocrystal Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our COCP earnings forecast.

How were Cocrystal Pharma's earnings last quarter?: Cocrystal Pharma, Inc. (NASDAQ:COCP) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.48) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.48).
When did Cocrystal Pharma's stock split?: Shares of Cocrystal Pharma reverse split on Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What other stocks do shareholders of Cocrystal Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).
How do I buy shares of Cocrystal Pharma?: Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:COCP) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cocrystal Pharma Stock Price, News & Analysis (NASDAQ:COCP)

Cocrystal Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Cocrystal Pharma Stock (NASDAQ:COCP)

COCP Stock Price History

COCP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

COCP Stock Analysis - Frequently Asked Questions

Overall MarketRank^™